{"mainPropery":{"diseaseId":9319,"diseaseName":"Chronic myeloproliferative disorders","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/9319/chronic-myeloproliferative-disorders","synonyms":[],"synonyms-with-source":[],"identifiers":[{"identifierType":"UMLS","identifierId":"C1292778"}]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":120,"resourceName":"American Cancer Society","abbreviation":"","address1":"250 Williams Street NW","address2":"","address3":"","address4":"","address5":"","city":"Atlanta","state":"GA","zip":"30329","country":"United States","phone":"","tty":"","tollFree":"1-800-227-2345","fax":"","email":"","url":"https://www.cancer.org","freeText":""},{"resourceID":570,"resourceName":"Leukemia and Lymphoma Society","abbreviation":"","address1":"3 International Drive, Suite 200","address2":"","address3":"","address4":"","address5":"","city":"Rye Brook","state":"NY","zip":"10573","country":"United States","phone":"1-(888) 557-7177 (general)","tty":"","tollFree":"1-(800) 955-4572 (patients and families)","fax":"","email":"https://www.lls.org/content/contact-us","url":"https://www.lls.org/","freeText":""}],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/pubmed?term=%22chronic%20myeloproliferative%20disorders%22' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Chronic myeloproliferative disorders. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Chronic+myeloproliferative+disorders%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Chronic myeloproliferative disorders. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/204714-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1543,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The <a href='http://www.cancer.gov/cancertopics/types/myeloproliferative' target='_blank'>National Cancer Institute</a> provides the most current information on cancer for patients, health professionals, and the general public.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1756,"resourceId":2916,"resourceName":"NORD Physician Guide","descriptionText":"The <a href='https://rarediseases.org/physician-guide/myleofibrosis/' target='_blank'>NORD Physician Guide</a> for Chronic myeloproliferative disorders was developed as a free service of the National Organization for Rare Disorders (NORD) and it's medical advisors. &nbsp;The guides provide a resource for clinicians about specific rare disorders to facilitate diagnosis and treatment of their patients with this condition.&nbsp;","resourceClassificationName":"Treatment","resourceClassificationSectionName":"Management Guidelines"},{"id":2160,"resourceId":3368,"resourceName":"Patient Access Network Foundation","descriptionText":"<a href='https://panfoundation.org/index.php/en/patients/assistance-programs/myelodysplastic-syndromes' target='_blank'>Patient Access Network Foundation</a> (PAN Foundation) has Assistance Programs for those with health insurance who reside in the United States. The disease fund status can change over time, so you may need to check back if funds are not currently available.&nbsp;","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":4270,"questionText":"What are chronic myeloproliferative disorders?","answerText":"<strong>Chronic myeloproliferative disorders</strong> are a group of slow-growing blood cancers in which the <a href=\"http://www.nlm.nih.gov/medlineplus/bonemarrowdiseases.html\">bone marrow</a>&nbsp;makes too many abnormal <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003644.htm\">red blood cells</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003643.htm\">white blood cells</a>, or <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003647.htm\">platelets</a>, which accumulate in the&nbsp;blood. The type of myeloproliferative disorder is based on whether too many red blood cells, white blood cells, or platelets are being made. Sometimes the body will make too many of more than one type of blood cell, but usually one type of blood cell is affected more than the others.[3213] <br />\r\n<br />\r\nThere are 6 types of chronic myeloproliferative disorders: <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000570.htm\" target=\"_blank\">chronic myelogenous leukemia</a>&nbsp;(CML), <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000589.htm\" target=\"_blank\">polycythemia vera</a>, <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000531.htm\" target=\"_blank\">primary myelofibrosis</a> (also called chronic idiopathic myelofibrosis), <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000543.htm\" target=\"_blank\">essential thrombocythemia</a>, <a href=\"https://www.cancer.gov/types/myeloproliferative/patient/chronic-treatment-pdq#section/_255\" target=\"_blank\">chronic neutrophilic leukemia</a>, and <a href=\"https://www.cancer.gov/types/myeloproliferative/patient/chronic-treatment-pdq#section/_258\" target=\"_blank\">chronic eosinophilic leukemia</a>. Chronic myeloproliferative disorders sometimes become acute leukemia, in which too many abnormal white blood cells are made.[3213]","dateModified":"2017-03-14T00:00:00"},"basicQuestions":[],"references":[],"relatedDiseases":[{"relatedDiseaseId":6105,"relatedDiseaseName":"Chronic myeloid leukemia","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":6594,"relatedDiseaseName":"Essential thrombocythemia","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":7422,"relatedDiseaseName":"Polycythemia vera","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":8618,"relatedDiseaseName":"Primary myelofibrosis","relation":"Child","isRare":true,"hasGardPage":true}],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[{"productId":518,"genericName":"Imatinib mesylate","tradeName":"GleevecÂ®","tradeLink":"http://www.gleevec.com/index.jsp?usertrack.filter_applied=true&NovaId=1178761786655757289","manufacturer":"","sponsor":"Novartis Pharmaceuticals Corp.","indication":"Treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) ","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Gleevec","medlinePlusLink":""}],"EncodedName":"Chronic_myeloproliferative_disorders"}